CA2453782A1 - Formulation de noyau comprenant de la troglitazone et un biguanide - Google Patents
Formulation de noyau comprenant de la troglitazone et un biguanide Download PDFInfo
- Publication number
- CA2453782A1 CA2453782A1 CA002453782A CA2453782A CA2453782A1 CA 2453782 A1 CA2453782 A1 CA 2453782A1 CA 002453782 A CA002453782 A CA 002453782A CA 2453782 A CA2453782 A CA 2453782A CA 2453782 A1 CA2453782 A1 CA 2453782A1
- Authority
- CA
- Canada
- Prior art keywords
- acid
- patient
- troglitazone
- glucopyranosyl
- core
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 title claims abstract 14
- 229960001641 troglitazone Drugs 0.000 title claims abstract 14
- GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 title claims abstract 14
- 239000000203 mixture Substances 0.000 title claims 23
- 238000009472 formulation Methods 0.000 title claims 10
- 229940123208 Biguanide Drugs 0.000 title claims 6
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 title claims 6
- 229960003105 metformin Drugs 0.000 claims abstract 9
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims abstract 9
- 238000013270 controlled release Methods 0.000 claims abstract 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims abstract 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 26
- 229920000642 polymer Polymers 0.000 claims 12
- 239000000741 silica gel Substances 0.000 claims 10
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 claims 10
- 235000012239 silicon dioxide Nutrition 0.000 claims 10
- 238000000034 method Methods 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 8
- 239000004480 active ingredient Substances 0.000 claims 7
- 206010012601 diabetes mellitus Diseases 0.000 claims 7
- 239000005995 Aluminium silicate Substances 0.000 claims 6
- 235000012211 aluminium silicate Nutrition 0.000 claims 6
- 229960000892 attapulgite Drugs 0.000 claims 6
- 239000000440 bentonite Substances 0.000 claims 6
- 229910000278 bentonite Inorganic materials 0.000 claims 6
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 claims 6
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 claims 6
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 claims 6
- 229910052618 mica group Inorganic materials 0.000 claims 6
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 claims 6
- 229910052625 palygorskite Inorganic materials 0.000 claims 6
- 239000008262 pumice Substances 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 239000000454 talc Substances 0.000 claims 6
- 229910052623 talc Inorganic materials 0.000 claims 6
- 239000002253 acid Substances 0.000 claims 5
- KDJOAYSYCXTQGG-UHFFFAOYSA-N disilicic acid Chemical compound O[Si](O)(O)O[Si](O)(O)O KDJOAYSYCXTQGG-UHFFFAOYSA-N 0.000 claims 5
- 229910021485 fumed silica Inorganic materials 0.000 claims 5
- 229910002027 silica gel Inorganic materials 0.000 claims 5
- 239000000377 silicon dioxide Substances 0.000 claims 5
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 claims 3
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 229910000077 silane Inorganic materials 0.000 claims 3
- 150000004756 silanes Chemical class 0.000 claims 3
- -1 siloxanes Chemical class 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 2
- 229960004111 buformin Drugs 0.000 claims 2
- XSEUMFJMFFMCIU-UHFFFAOYSA-N buformin Chemical compound CCCC\N=C(/N)N=C(N)N XSEUMFJMFFMCIU-UHFFFAOYSA-N 0.000 claims 2
- 239000011248 coating agent Substances 0.000 claims 2
- 238000000576 coating method Methods 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 229960003243 phenformin Drugs 0.000 claims 2
- ICFJFFQQTFMIBG-UHFFFAOYSA-N phenformin Chemical compound NC(=N)NC(=N)NCCC1=CC=CC=C1 ICFJFFQQTFMIBG-UHFFFAOYSA-N 0.000 claims 2
- 238000000151 deposition Methods 0.000 claims 1
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical compound O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 239000004005 microsphere Substances 0.000 claims 1
- 238000007789 sealing Methods 0.000 claims 1
- 229940000425 combination drug Drugs 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
L'invention concerne un produit pharmaceutique combiné à libération contrôlée, notamment son chlorhydrate, et un biguamide, tel que la metformine. Le produit de l'invention contient plus particulièrement un noyau de metformine dont au moins une partie possède une couche de troglitazone.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2001/021616 WO2003005993A1 (fr) | 2000-05-01 | 2001-07-10 | Formulation de noyau comprenant de la troglitazone et un biguanide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2453782A1 true CA2453782A1 (fr) | 2003-01-23 |
Family
ID=32067644
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002453782A Abandoned CA2453782A1 (fr) | 2001-07-10 | 2001-07-10 | Formulation de noyau comprenant de la troglitazone et un biguanide |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1429740A4 (fr) |
| JP (1) | JP2004536842A (fr) |
| AU (1) | AU2001273290B2 (fr) |
| CA (1) | CA2453782A1 (fr) |
| MX (1) | MXPA04000181A (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7785627B2 (en) * | 2002-09-20 | 2010-08-31 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6416774B1 (en) * | 1996-05-09 | 2002-07-09 | The Trustees Of The University Of Pennsyvania | Hollow bone mineral-like calcium phosphate particles |
| US6011049A (en) * | 1997-02-19 | 2000-01-04 | Warner-Lambert Company | Combinations for diabetes |
| PL347634A1 (en) * | 1998-11-12 | 2002-04-22 | Smithkline Beecham Plc | Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent |
| DE19860699A1 (de) * | 1998-12-30 | 2000-07-06 | Hexal Ag | Pharmazeutische Zusammensetzung |
| US6358531B1 (en) * | 1999-02-01 | 2002-03-19 | The Curators Of The University Of Missouri | Method for preparing porous shells or gels from glass particles |
| AR030920A1 (es) * | 1999-11-16 | 2003-09-03 | Smithkline Beecham Plc | Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus, y procedimientos para preparar dichas composiciones |
| AU1403501A (en) * | 1999-11-16 | 2001-05-30 | Smithkline Beecham Plc | Novel composition and use |
| US6451342B2 (en) * | 2000-05-01 | 2002-09-17 | Aeropharm Technology Incorporated | Core formulation comprised of troglitazone and a biguanide |
-
2001
- 2001-07-10 JP JP2003511800A patent/JP2004536842A/ja active Pending
- 2001-07-10 AU AU2001273290A patent/AU2001273290B2/en not_active Ceased
- 2001-07-10 EP EP01952549A patent/EP1429740A4/fr not_active Withdrawn
- 2001-07-10 CA CA002453782A patent/CA2453782A1/fr not_active Abandoned
- 2001-07-10 MX MXPA04000181A patent/MXPA04000181A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2004536842A (ja) | 2004-12-09 |
| EP1429740A4 (fr) | 2005-01-26 |
| EP1429740A1 (fr) | 2004-06-23 |
| MXPA04000181A (es) | 2004-11-22 |
| AU2001273290B2 (en) | 2004-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6524621B2 (en) | Core formulation | |
| US6451342B2 (en) | Core formulation comprised of troglitazone and a biguanide | |
| US6403121B1 (en) | Core formulation | |
| US6780432B1 (en) | Core formulation | |
| US6296874B1 (en) | Core formulation comprising troglitazone and abiguanide | |
| US6461639B2 (en) | Core formulation | |
| IL158506A (en) | Oral pharmaceutical form for a single daily intake combining a metformin and at least one other antidiabetic active principle | |
| CA2084568A1 (fr) | Medicaments pour traiter les troubles inflammatoires ou comme analgesiques | |
| AU2001273289B2 (en) | Core formulation comprising pioglitazone hydrochloride and a biguanide | |
| KR100732599B1 (ko) | 조절 방출형 인슐린 감작제용 제약 조성물 | |
| US10045973B2 (en) | Compositions and methods for treating nocturnal acid breakthrough and other related disorders | |
| AU2001273289A1 (en) | Core formulation comprising pioglitazone hydrochloride and a biguanide | |
| AU2001273310B2 (en) | A core formulation | |
| EP1278513B1 (fr) | Formulation de noyaux | |
| AU2001273310A1 (en) | A core formulation | |
| AU2001257456A1 (en) | A core formulation | |
| AU2001273290B2 (en) | Core formulation comprising troglitazone and a biguanide | |
| AU2001273290A1 (en) | Core formulation comprising troglitazone and a biguanide | |
| AU2005231479C1 (en) | (R,R)-formoterol in combination with other pharmacological agents | |
| HK1095277A (en) | Gastric acid secretion inhibiting composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |